Corcept Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CEOJoseph K. Belanoff
CEOJoseph K. Belanoff
Employees500
Employees500
HeadquartersRedwood City, California
HeadquartersRedwood City, California
Founded1998
Founded1998
Employees500
Employees500
CORT Key Statistics
Market cap7.56B
Market cap7.56B
Price-Earnings ratio61.96
Price-Earnings ratio61.96
Dividend yield—
Dividend yield—
Average volume1.32M
Average volume1.32M
High today$72.21
High today$72.21
Low today$68.92
Low today$68.92
Open price$70.63
Open price$70.63
Volume1.22M
Volume1.22M
52 Week high$117.33
52 Week high$117.33
52 Week low$25.35
52 Week low$25.35
CORT News
TipRanks 3d
Corcept Therapeutics price target lowered to $135 from $150 at TruistTruist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1...
TipRanks 3d
Corcept Therapeutics Reports Q1 2025 Financial ResultsCorcept Therapeutics ( (CORT) ) has provided an update. On May 5, 2025, Corcept Therapeutics announced its financial results for the first quarter of 2025, rep...
People also own
Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.